Home > Publications database > Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. > print

001     179556
005     20240918080814.0
024 7 _ |a 10.1038/s41598-022-10121-2
|2 doi
024 7 _ |a pmid:35418701
|2 pmid
024 7 _ |a pmc:PMC9007944
|2 pmc
024 7 _ |a altmetric:126589623
|2 altmetric
037 _ _ |a DKFZ-2022-00734
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Wang, Xiaoliang
|b 0
245 _ _ |a Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.
260 _ _ |a [London]
|c 2022
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726639674_5616
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values < 5 × 10-8 as genome-wide significant, and p-values < 1 × 10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants. None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values < 1 × 105. The strongest evidence was found for rs4674019 (p-value = 2.27 × 10-7), which showed genome-wide significant interaction (p-value = 3.8 × 10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT-breast cancer risk association.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 2 |a Breast
|2 MeSH
650 _ 2 |a Breast Neoplasms: chemically induced
|2 MeSH
650 _ 2 |a Breast Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Breast Neoplasms: genetics
|2 MeSH
650 _ 2 |a Estrogen Replacement Therapy: adverse effects
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Hormone Replacement Therapy: adverse effects
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Menopause
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
700 1 _ |a Kapoor, Pooja Middha
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Auer, Paul L
|b 2
700 1 _ |a Dennis, Joe
|b 3
700 1 _ |a Dunning, Alison M
|b 4
700 1 _ |a Wang, Qin
|b 5
700 1 _ |a Lush, Michael
|b 6
700 1 _ |a Michailidou, Kyriaki
|b 7
700 1 _ |a Bolla, Manjeet K
|b 8
700 1 _ |a Aronson, Kristan J
|b 9
700 1 _ |a Murphy, Rachel A
|b 10
700 1 _ |a Brooks-Wilson, Angela
|b 11
700 1 _ |a Lee, Derrick G
|b 12
700 1 _ |a Cordina-Duverger, Emilie
|b 13
700 1 _ |a Guénel, Pascal
|b 14
700 1 _ |a Truong, Thérèse
|b 15
700 1 _ |a Mulot, Claire
|b 16
700 1 _ |a Teras, Lauren R
|b 17
700 1 _ |a Patel, Alpa V
|b 18
700 1 _ |a Dossus, Laure
|b 19
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 20
|u dkfz
700 1 _ |a Hoppe, Reiner
|b 21
700 1 _ |a Lo, Wing-Yee
|b 22
700 1 _ |a Brüning, Thomas
|b 23
700 1 _ |a Hamann, Ute
|0 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
|b 24
|u dkfz
700 1 _ |a Czene, Kamila
|b 25
700 1 _ |a Gabrielson, Marike
|b 26
700 1 _ |a Hall, Per
|b 27
700 1 _ |a Eriksson, Mikael
|b 28
700 1 _ |a Jung, Audrey
|0 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
|b 29
|u dkfz
700 1 _ |a Becher, Heiko
|b 30
700 1 _ |a Couch, Fergus J
|b 31
700 1 _ |a Larson, Nicole L
|b 32
700 1 _ |a Olson, Janet E
|b 33
700 1 _ |a Ruddy, Kathryn J
|b 34
700 1 _ |a Giles, Graham G
|b 35
700 1 _ |a MacInnis, Robert J
|b 36
700 1 _ |a Southey, Melissa C
|b 37
700 1 _ |a Le Marchand, Loic
|b 38
700 1 _ |a Wilkens, Lynne R
|b 39
700 1 _ |a Haiman, Christopher A
|b 40
700 1 _ |a Olsson, Håkan
|b 41
700 1 _ |a Augustinsson, Annelie
|b 42
700 1 _ |a Krüger, Ute
|b 43
700 1 _ |a Wagner, Philippe
|b 44
700 1 _ |a Scott, Christopher
|b 45
700 1 _ |a Winham, Stacey J
|b 46
700 1 _ |a Vachon, Celine M
|b 47
700 1 _ |a Perou, Charles M
|b 48
700 1 _ |a Olshan, Andrew F
|b 49
700 1 _ |a Troester, Melissa A
|b 50
700 1 _ |a Hunter, David J
|b 51
700 1 _ |a Eliassen, Heather A
|b 52
700 1 _ |a Tamimi, Rulla M
|b 53
700 1 _ |a Brantley, Kristen
|b 54
700 1 _ |a Andrulis, Irene L
|b 55
700 1 _ |a Figueroa, Jonine
|b 56
700 1 _ |a Chanock, Stephen J
|b 57
700 1 _ |a Ahearn, Thomas U
|b 58
700 1 _ |a García-Closas, Montserrat
|b 59
700 1 _ |a Evans, Gareth D
|b 60
700 1 _ |a Newman, William G
|b 61
700 1 _ |a van Veen, Elke M
|b 62
700 1 _ |a Howell, Anthony
|b 63
700 1 _ |a Wolk, Alicja
|b 64
700 1 _ |a Håkansson, Niclas
|b 65
700 1 _ |a Anton-Culver, Hoda
|b 66
700 1 _ |a Ziogas, Argyrios
|b 67
700 1 _ |a Jones, Michael E
|b 68
700 1 _ |a Orr, Nick
|b 69
700 1 _ |a Schoemaker, Minouk J
|b 70
700 1 _ |a Swerdlow, Anthony J
|b 71
700 1 _ |a Kitahara, Cari M
|b 72
700 1 _ |a Linet, Martha
|b 73
700 1 _ |a Prentice, Ross L
|b 74
700 1 _ |a Easton, Douglas F
|b 75
700 1 _ |a Milne, Roger L
|b 76
700 1 _ |a Kraft, Peter
|b 77
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 78
|u dkfz
700 1 _ |a Lindström, Sara
|b 79
773 _ _ |a 10.1038/s41598-022-10121-2
|g Vol. 12, no. 1, p. 6199
|0 PERI:(DE-600)2615211-3
|n 1
|p 6199
|t Scientific reports
|v 12
|y 2022
|x 2045-2322
909 C O |p VDB
|o oai:inrepo02.dkfz.de:179556
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 78
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-08-08T09:38:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-08-08T09:38:07Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-08-08T09:38:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-09
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)B072-20160331
|k B072
|l Molekulargenetik des Mammakarzinoms
|x 1
920 1 _ |0 I:(DE-He78)B070-20160331
|k B070
|l B070 Funktionelle Genomanalyse
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B072-20160331
980 _ _ |a I:(DE-He78)B070-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21